1
|
Lee H, Fong L, Fung S, Kwok F, Ching O, Fong H, Ng M, Coiffier B. Prognostic Significance Of Coronary Artery Calcium Scoring In Breast Cancer Patients. J Cardiovasc Comput Tomogr 2020. [DOI: 10.1016/j.jcct.2020.06.107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
2
|
Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 2019; 29:1822-1827. [PMID: 29897404 DOI: 10.1093/annonc/mdy203] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Background Patients with diffuse large B-cell lymphoma treated with first-line anthracycline-based immunochemotherapy and remaining in remission at 2 years have excellent outcomes. This study assessed overall survival (OS) stratified by progression-free survival (PFS) at 24 months (PFS24) using individual patient data from patients with DLBCL enrolled in multi-center, international randomized clinical trials as part of the Surrogate Endpoint for Aggressive Lymphoma (SEAL) Collaboration. Patients and methods PFS24 was defined as being alive and PFS24 after study entry. OS from PFS24 was defined as time from identified PFS24 status until death due to any cause. OS was compared with each patient's age-, sex-, and country-matched general population using expected survival and standardized mortality ratios (SMRs). Results A total of 5853 patients enrolled in trials in the SEAL database received rituximab as part of induction therapy and were included in this analysis. The median age was 62 years (range 18-92), and 56% were greater than 60 years of age. At a median follow-up of 4.4 years, 1337 patients (23%) had disease progression, 1489 (25%) had died, and 5101 had sufficient follow-up to evaluate PFS24. A total of 1423 assessable patients failed to achieve PFS24 with a median OS of 7.2 months (95% CI 6.8-8.1) after progression; 5-year OS after progression was 19% and SMR was 32.1 (95% CI 30.0-34.4). A total of 3678 patients achieved PFS24; SMR after achieving PFS24 was 1.22 (95% CI 1.09-1.37). The observed OS versus expected OS at 3, 5, and 7 years after achieving PFS24 was 93.1% versus 94.4%, 87.6% versus 89.5%, and 80.0% versus 83.7%, respectively. Conclusion Patients treated with rituximab containing anthracycline-based immunochemotherapy on clinical trials who are alive without progression at 24 months from the onset of initial therapy have excellent outcomes with survival that is marginally lower but clinically indistinguishable from the age-, sex-, and country-matched background population for 7 years after achieving PFS24.
Collapse
Affiliation(s)
- M J Maurer
- Department of Health Sciences Research, Mayo Clinic, Rochester, USA.
| | | | - Q Shi
- Department of Health Sciences Research, Mayo Clinic, Rochester, USA
| | - N Schmitz
- Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St. Georg, Hamburg, Germany
| | - D Cunningham
- Department of Medicine, The Royal Marsden Hospital, Surrey, UK
| | - M Pfreundschuh
- Internal Medicine I, University of the Saarland, Homberg, Germany
| | - J F Seymour
- Peter MacCallum Cancer Centre, Melbourne, Australia
| | - U Jaeger
- Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - C Haioun
- Lymphoid Malignancies Unit, AP-HP Hôpital Henri Mondor, Créteil, France
| | - H Tilly
- Henri Becquerel Centre, University of Rouen, Rouen, France
| | - H Ghesquieres
- Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
| | - F Merli
- Hematology, Azienda Ospedaliera Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
| | - M Ziepert
- Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - R Herbrecht
- Department of Oncology and Hematology, Hôpital de Hautepierre, Strasbourg, France
| | - J Flament
- Celgene Corporation, Boudry, Switzerland
| | - T Fu
- Celgene Corporation, Summit
| | - C R Flowers
- Department of Bone Marrow and Stem Cell Transplantation, Winship Cancer Institute of Emory University, Atlanta, USA
| | - B Coiffier
- Department of Hematology, Centre Hospitalier Lyon-Sud, Pierre-Benite, France
| |
Collapse
|
3
|
Affiliation(s)
- G Follea
- Service de réanimation, Service des maladies du sang, Hôpital Edouard Herriot
| | - B Coiffier
- Service de réanimation, Service des maladies du sang, Hôpital Edouard Herriot
- Laboratoire d’Hémobiologie, Faculté Alexis Carrel, Institut Pasteur, rue Guillaume Paradin, 69008 Lyon, France
| | - J P Viale
- Service de réanimation, Service des maladies du sang, Hôpital Edouard Herriot
- Laboratoire d’Hémobiologie, Faculté Alexis Carrel, Institut Pasteur, rue Guillaume Paradin, 69008 Lyon, France
| | - M Dechavanne
- Service de réanimation, Service des maladies du sang, Hôpital Edouard Herriot
- Laboratoire d’Hémobiologie, Faculté Alexis Carrel, Institut Pasteur, rue Guillaume Paradin, 69008 Lyon, France
| |
Collapse
|
4
|
Kim W, Coiffier B, Buske C, Ogura M, Kwak L, Jurczak W, Sancho J, Zhavrid E, Kim J, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Lee S, Lee S, Bae Y. CT-P10 versus reference rituximab in combination with CVP in advanced-stage follicular lymphoma: Phase 3, double-blind, randomized trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx664.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
6
|
Sarkozy C, Coiffier B. Diffuse large B-cell lymphoma (DLBCL), 2 versus 3: end of a debate? Ann Oncol 2017; 28:1411-1413. [DOI: 10.1093/annonc/mdx249] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2017] [Indexed: 01/01/2023] Open
|
7
|
Buske C, Kim W, Kwak L, Coiffier B, Jurczak W, Sancho J, Zhavrid E, Kim J, Hernández Rivas J, Prokharau A, Vasilica M, Nagarkar R, Osmanov D, Lee S, Lee S, Bae Y, Ogura M. A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_83] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Buske
- CCC Ulm; University Hospital of Ulm; Ulm Germany
| | - W. Kim
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center; Sungkyunkwan University School of Medicine; Seoul Republic of Korea
| | - L. Kwak
- Toni Stephenson Lymphoma Center and Department of Haematology and Hematopoietic Cell Transplantation, City of Hope Duarte; Duarte USA
| | - B. Coiffier
- Department of Hematology; Hospices Civils de Lyon; Lyon France
| | - W. Jurczak
- Department of Haematology; Jagiellonian University; Kraków Poland
| | - J.M. Sancho
- Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol; Badalona Spain
| | - E. Zhavrid
- Department of Haematology; N.N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology; Minsk Belarus
| | - J. Kim
- Department of Internal Medicine; Yonsei University College of Medicine, Severance Hospital; Seoul Korea, Republic of
| | | | - A. Prokharau
- Department of Haematology, Minsk City Clinical Oncology Dispensary; Minsk Belarus
| | - M. Vasilica
- Hematology Department; Fundeni Clinical Institute; Bucharest Romania
| | - R. Nagarkar
- Curie Manavata Cancer Centre, Curie Manavata Cancer Centre; Maharashtra India
| | - D. Osmanov
- Department of Chemotherapy of Hemoblastosis, N.N. Blokhin Russian Cancer Research Center; Moscow Russian Federation
| | - S. Lee
- Clinical Development Division; CELLTRION, Inc.; Incheon Korea, Republic of
| | - S. Lee
- Clinical Development Division; CELLTRION, Inc.; Incheon Korea, Republic of
| | - Y. Bae
- Clinical Development Division; CELLTRION, Inc.; Incheon Korea, Republic of
| | - M. Ogura
- Department of Haematology, Tokai Central Hospital, Kakamigahara; Gifu Japan
| |
Collapse
|
8
|
Federico M, Caballero D, Marcheselli L, Tarantino V, Sarkozy C, Lopez Guillermo A, Wondergem M, Kimby E, Rusconi C, Zucca E, Montoto S, da Silva M, Aurer I, Paszkiewicz-Kozik E, Cartron G, Morschhauser F, Alcoceba M, Chamuleau M, Lockmer S, Minoia C, Issa D, Alonso S, Conte L, Salles G, Coiffier B. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_104] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - D. Caballero
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - V. Tarantino
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - C. Sarkozy
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| | - A. Lopez Guillermo
- Department of Hematology; Hospital Clinic, IDIBAPS, CIBERONC; Barcelona Spain
| | - M. Wondergem
- Department of Hematology; VU University Medical Center; Amsterdam Netherlands
| | - E. Kimby
- Department of Hematology; Karolinska Institute; Stockholm Sweden
| | - C. Rusconi
- Division of Hematology; Niguarda Hospital; Milan Italy
| | - E. Zucca
- Oncology Institute of Southern Switzerland; Ospedale San Giovanni; Bellinzona Switzerland
| | - S. Montoto
- Department of Hematology; Barts Cancer Institute, QMUL; London UK
| | - M.G. da Silva
- Department of Hematology; Instituto Português de Oncologia de Lisboa; Lisbon Portugal
| | - I. Aurer
- Division of Hematology; University Hospital Centre Zagreb; Zagreb Croatia
| | - E. Paszkiewicz-Kozik
- Department of Lymphoid Malignancies; The Maria Sklodowska-Curie Memorial Institute and Oncology Centre; Warszawa Poland
| | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - F. Morschhauser
- Department of Clinical Hematology, CHU Lille, Unite GRITA; Universite de Lille 2; Lille France
| | - M. Alcoceba
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - M. Chamuleau
- Department of Hematology; VU University Medical Center; Amsterdam Netherlands
| | - S. Lockmer
- Department of Hematology; Karolinska Institute; Stockholm Sweden
| | - C. Minoia
- Haematology Unit, National Cancer Research Centre; Istituto Tumori "Giovanni Paolo II"; Bari Italy
| | - D. Issa
- Department of Hematology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch; Netherlands
| | - S. Alonso
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Conte
- Interdisciplinary Laboratory of Applied Research in Medicine (DReAM); University of Salento; Lecce Italy
| | - G. Salles
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| | - B. Coiffier
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| |
Collapse
|
9
|
Delfau-Larue M, Beldi-Ferchiou A, Jais J, Godard N, Salles G, Casasnovas R, Tilly H, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Perrot A, Sebban C, Bouabdallah R, Gonzalez H, Corront B, Oberic L, Briere J, Gaulard P, Coiffier B, Thieblemont C. LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE: a LYSA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M.H. Delfau-Larue
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - A. Beldi-Ferchiou
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - J. Jais
- Biostatistics Unit, APHP; Univ Paris Descartes; Paris France
| | - N. Godard
- Biological Hematology and Immunology department, APHP, Groupe Hospitalier Mondor, INSERM U 955; Creteil France
| | - G.A. Salles
- Hematology; Centre Hospitalier Lyon Sud; Pierre-Benite France
| | - R. Casasnovas
- Hematology; CHU Dijon - Hopital du Bocage; Dijon France
| | - H. Tilly
- INSERM U918; Centre Henri Becquerel; Rouen France
| | - C. Fruchart
- Institut d'Hématologie de Basse Normandie; CHU Caen; Caen France
| | | | - C. Haioun
- Lymphoid Malignancies Unit, APHP, Groupe Hospitalier Mondor; Creteil France
| | - J. Lazarovici
- Clinical Hematology, Gustave Roussy Cancer Center; Villejuif France
| | - A. Perrot
- Hematology department, CHU Brabois; Vandoeuvre les Nancy France
| | - C. Sebban
- Onco Hematology; Centre Leon Berard; Lyon France
| | - R. Bouabdallah
- Onco Hematology; Institut Paoli Calmettes; Marseille France
| | | | - B. Corront
- Hematology; CH Annecy Genevois, Epagny Metz-Tessy; France
| | - L. Oberic
- Hematology; IUC - Oncopole CHU Toulouse; Toulouse France
| | - J. Briere
- Pathology; APHP, Hopital Saint-Louis; Paris France
| | - P. Gaulard
- Pathology; APHP, Hopital Henri Mondor; Creteil France
| | - B. Coiffier
- CNRS UMR5239; Centre Hospitalier Lyon Sud; Pierre Benite France
| | - C. Thieblemont
- Hemato-Oncology, APHP; Hopital Saint-Louis; Paris France
| |
Collapse
|
10
|
Canioni D, Brice P, Bologna S, Voillat L, Gabarre J, Casasnovas O, Devidas A, Coiffier B, Aoudjhane A, Audouy B, Andre M, Fortpied C, Carde P, Mounier N, Briere J. PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN STAGE III/IV CLASSICAL HODGKIN LYMPHOMA TREATED FRONTLINE IN THE LYSA EORTC 20012 RANDOMIZED PROTOCOL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- D. Canioni
- Pathology Department; Hopital Necker; Paris France
| | - P. Brice
- Hematology Department; Hopital Saint-Louis; France
| | - S. Bologna
- Meurte-Moselle; Centre d'Oncologie de Gentilly, Essey-les Nancy; France
| | - L. Voillat
- Hematology Department; Centre Hospitalier de Chalon sur Saône, Chalon sur Saone; France
| | - J. Gabarre
- Hematology Department; Hopital Pitié-Salpétrière; France
| | | | - A. Devidas
- Hematology Department; CH de Corbeil-Essones; Corbeil- Essones France
| | - B. Coiffier
- Hematology Department; Hospices Civils de Lyon; Pierre Bénite France
| | - A. Aoudjhane
- Hematology Department; Hopital Saint-Antoine; France
| | - B. Audouy
- Hematology Department; CH de Colmar; Colmar France
| | - M. Andre
- Hematology Department; CH de Mont Godinne; Yvoir Belgium
| | | | - P. Carde
- Hematology Department; Hopital Américain, Neuillyè-sur-Seine; France
| | - N. Mounier
- Hematology Department; Hopital de l'Archet; Nice France
| | - J. Briere
- Pathology Department; Hopital Necker; Paris France
| |
Collapse
|
11
|
Thieblemont C, Casasnovas R, Mounier N, Perrot A, Morschhauser F, Tilly H, Fruchart C, Corront B, Haouin C, Van Eygen K, Obéric L, Bouabdallah R, Sebban C, Bordessoule D, Fitoussi O, Van Hoof A, Eisenmann J, Lionne-Huyghe P, Deeren D, Gomes Da Silva M, Trotman J, Grosicki S, Greil R, Caballero D, Coiffier B. REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_91] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C. Thieblemont
- Hemato-Oncology, APHP; Hôpital Saint-Louis; Paris France
| | - R. Casasnovas
- Service d'Hématologie Clinique; CHU Dijon and INSERM UMR1231; Dijon France
| | - N. Mounier
- Service d'Onco-Hématologie, CHU Nice, Hôpital Archet 1; Nice France
| | - A. Perrot
- Hematology Department; University Hospital; Vandoeuvre Les Nancy France
| | - F. Morschhauser
- Institute of Hematology-Transfusion; Centre Hospitalier Universitaire Régional de Lille; Lille France
| | - H. Tilly
- Department of Hematology, Centre Henri Becquerel; UNIROUEN, INSERMU1245; Rouen France
| | - C. Fruchart
- Hématologie; Institut d'Hématologie de Basse Normandie, CHU; Caen France
| | - B. Corront
- Service d'Hématologie Clinique, CHR Annecy; Annecy France
| | - C. Haouin
- Lymphoid Malignancies Unit, AP-HP; Groupe Hospitalier Mondor; Créteil France
| | - K. Van Eygen
- Oncologisch centrum; AZ Groeninge Hospital, President Kennedylaan 4; Kortrijk Belgium
| | - L. Obéric
- Département d'Hématologie; Institut Universitaire du Cancer-Oncopole de Toulouse; Toulouse France
| | - R. Bouabdallah
- Department of Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Sebban
- Onco-hematology, Centre Leon Berard; University Claude Bernard Lyon 1; Lyon France
| | - D. Bordessoule
- Hematology; CHU de Limoges - Hôpital Universitaire Dupuytren; Limoges France
| | - O. Fitoussi
- Hematology/Oncology; Polyclinique Bordeaux Nord Aquitaine; Bordeaux France
| | - A. Van Hoof
- Hematologie, A.Z. Sint Jan AV; Brugge Belgium
| | | | | | - D. Deeren
- Hematologie, AZ Delta; Roeselare Belgium
| | - M. Gomes Da Silva
- Hematology; Insituto Portuges de Oncologia de Lisboa; Lisbon Portugal
| | - J. Trotman
- Haematology Department, Concord Repatriation General Hospital; University of Sydney; Concord Australia
| | - S. Grosicki
- Department of Cancer Prevention, School of Public Health; Medical University of Silesia; Katowice Poland
| | - R. Greil
- IIIrd Medical Department, Paracelsus Medical University Salzburg; Salzburg Cancer Research Institute; Salzburg Austria
| | - D. Caballero
- Department of Hematology/IBSAL; Hospital Universitario de Salamanca; Salamanca Spain
| | - B. Coiffier
- Department of Hematology, INSERM U1052 Hospices Civils de Lyon; Pierre-Bénite France
| |
Collapse
|
12
|
Lassau N, Coiffier B, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Benatsou B, Bonastre J, Koscielny S. Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab. Ann Oncol 2016; 27:1922-8. [PMID: 27502701 DOI: 10.1093/annonc/mdw280] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Accepted: 07/06/2016] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Dynamic contrast-enhanced ultrasonography (DCE-US) has been used for evaluation of tumor response to antiangiogenic treatments. The objective of this study was to assess the link between DCE-US data obtained during the first week of treatment and subsequent tumor progression. PATIENTS AND METHODS Patients treated with antiangiogenic therapies were included in a multicentric prospective study from 2007 to 2010. DCE-US examinations were available at baseline and at day 7. For each examination, a 3 min perfusion curve was recorded just after injection of a contrast agent. Each perfusion curve was modeled with seven parameters. We analyzed the correlation between criteria measured up to day 7 on freedom from progression (FFP). The impact was assessed globally, according to tumor localization and to type of treatment. RESULTS The median follow-up was 20 months. The mean transit time (MTT) evaluated at day 7 was the only criterion significantly associated with FFP (P = 0.002). The cut-off point maximizing the difference between FFP curves was 12 s. Patients with at least a 12 s MTT had a better FFP. The results according to tumor type were significantly heterogeneous: the impact of MTT on FFP was more marked for breast cancer (P = 0.004) and for colon cancer (P = 0.025) than for other tumor types. Similarly, the differences in FFP according to MTT at day 7 were marked (P = 0.004) in patients receiving bevacizumab. CONCLUSION The MTT evaluated with DCE-US at day 7 is significantly correlated to FFP of patients treated with bevacizumab. This criterion might be linked to vascular normalization. AFSSAPS NO 2007-A00399-44.
Collapse
Affiliation(s)
- N Lassau
- Gustave Roussy, Université Paris-Saclay, Imaging Department, Villejuif, and IR4M, Centre National de la Recherche Scientifique, Université Paris-Sud, Université Paris-Saclay, Villejuif
| | - B Coiffier
- Gustave Roussy, Université Paris-Saclay, Imaging Department, Villejuif, and IR4M, Centre National de la Recherche Scientifique, Université Paris-Sud, Université Paris-Saclay, Villejuif
| | - M Kind
- Imaging Department, Institut Bergonié, Bordeaux
| | - V Vilgrain
- Radiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Clichy
| | - J Lacroix
- Radiology Department, Centre François Baclesse, Caen
| | - M Cuinet
- Radiology Department, Centre Léon Bérard, Lyon
| | - S Taieb
- Radiology Department, Centre Oscar Lambret, Lille
| | - R Aziza
- Radiodiagnostics Department, Centre Claudius Regaud, Toulouse
| | - A Sarran
- Imaging Department, Institut Paoli Calmettes, Marseille
| | | | - B Gallix
- Department of Abdominal and Digestive Imaging, Hôpital Saint-Eloi, Montpellier and Department of Radiology, McGill University Health Center, Montreal, Canada
| | - O Lucidarme
- Radiology Department, CHU La Pitié-Salpêtrière, Paris
| | - Y Ptak
- Radiodiagnostics Department, Centre Jean Perrin, Clermont-Ferrand
| | - L Rocher
- Radiology Department, CHU Bicêtre, Le Kremlin-Bicêtre
| | - L M Caquot
- Radiodiagnostics and Imaging Department, Institut Jean Godinot, Reims
| | - S Chagnon
- Radiology Department, Hôpital Ambroise Paré, Boulogne-Billancourt
| | - D Marion
- Radiology Department, CHU Hôtel-Dieu, Lyon
| | - A Luciani
- Radiology Department, CHU Henri Mondor, Créteil
| | - S Feutray
- Radiology Department, Centre Georges-François Leclerc, Dijon
| | | | - B Benatsou
- Gustave Roussy, Université Paris-Saclay, Imaging Department, Villejuif, and IR4M, Centre National de la Recherche Scientifique, Université Paris-Sud, Université Paris-Saclay, Villejuif
| | - J Bonastre
- Service biostatistique et épidémiologie, Gustave Roussy and CESP Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris-Sud Univ., Villejuif, France
| | - S Koscielny
- Service biostatistique et épidémiologie, Gustave Roussy and CESP Centre for Research in Epidemiology and Population Health, INSERM U1018, Paris-Sud Univ., Villejuif, France
| |
Collapse
|
13
|
Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers M, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. Ann Oncol 2016; 27:390-7. [DOI: 10.1093/annonc/mdv616] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Accepted: 11/30/2015] [Indexed: 12/17/2022] Open
|
14
|
Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 2015; 26:774-779. [PMID: 25605745 PMCID: PMC4374388 DOI: 10.1093/annonc/mdv010] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Revised: 12/19/2014] [Accepted: 12/23/2014] [Indexed: 11/30/2022] Open
Abstract
BACKGROUND For patients with peripheral T-cell lymphoma (PTCL), the value of (18)fluoro-deoxyglucose positron emission tomography (FDG-PET) scans for assessing prognosis and response to treatment remains unclear. The utility of FDG-PET, in addition to conventional radiology, was examined as a planned exploratory end point in the pivotal phase 2 trial of romidepsin for the treatment of relapsed/refractory PTCL. PATIENTS AND METHODS Patients received romidepsin at a dose of 14 mg/m(2) on days 1, 8, and 15 of 28-day cycles. The primary end point was the rate of confirmed/unconfirmed complete response (CR/CRu) as assessed by International Workshop Criteria (IWC) using conventional radiology. For the exploratory PET end point, patients with at least baseline FDG-PET scans were assessed by IWC + PET criteria. RESULTS Of 130 patients, 110 had baseline FDG-PET scans, and 105 were PET positive at baseline. The use of IWC + PET criteria increased the objective response rate to 30% compared with 26% by conventional radiology. Durations of response were well differentiated by both conventional radiology response criteria [CR/CRu versus partial response (PR), P = 0.0001] and PET status (negative versus positive, P < 0.0001). Patients who achieved CR/CRu had prolonged progression-free survival (PFS, median 25.9 months) compared with other response groups (P = 0.0007). Patients who achieved PR or stable disease (SD) had similar PFS (median 7.2 and 6.3 months, respectively, P = 0.6427). When grouping PR and SD patients by PET status, patients with PET-negative versus PET-positive disease had a median PFS of 18.2 versus 7.1 months (P = 0.0923). CONCLUSIONS Routine use of FDG-PET does not obviate conventional staging, but may aid in determining prognosis and refine response assessments for patients with PTCL, particularly for those who do not achieve CR/CRu by conventional staging. The optimal way to incorporate FDG-PET scans for patients with PTCL remains to be determined. TRIAL REGISTRATION NCT00426764.
Collapse
MESH Headings
- Antibiotics, Antineoplastic/therapeutic use
- Depsipeptides/therapeutic use
- Drug Resistance, Neoplasm/drug effects
- Fluorodeoxyglucose F18/pharmacokinetics
- Follow-Up Studies
- Humans
- Lymphoma, T-Cell, Peripheral/diagnostic imaging
- Lymphoma, T-Cell, Peripheral/drug therapy
- Lymphoma, T-Cell, Peripheral/mortality
- Lymphoma, T-Cell, Peripheral/pathology
- Neoplasm Staging
- Positron-Emission Tomography/statistics & numerical data
- Prognosis
- Prospective Studies
- Radiopharmaceuticals/pharmacokinetics
- Remission Induction
- Survival Rate
- Tissue Distribution
Collapse
Affiliation(s)
- S Horwitz
- Lymphoma Division, Memorial Sloan-Kettering Cancer Center, New York, USA.
| | - B Coiffier
- Department of Hematology, Hospices Civils de Lyon, Lyon, France
| | - F Foss
- Hematology Department, Yale Cancer Center, New Haven, USA
| | - H M Prince
- Division of Cancer Medicine, Department of Haematology, Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - L Sokol
- Department of Malignant Hematology, Moffitt Cancer Center, Tampa, USA
| | - M Greenwood
- Department of Haematology, Royal North Shore Hospital, Sydney, Australia
| | - D Caballero
- Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain
| | - F Morschhauser
- Department of Hematology, Hôpital Claude Huriez, CHU de Lille, France
| | - L Pinter-Brown
- Division of Hematology-Oncology, UCLA Medical Center, Los Angeles
| | - S P Iyer
- Malignant Hematology, Houston Methodist Cancer Center, Houston
| | - A Shustov
- Division of Hematology, University of Washington, Seattle
| | | | | | | | - B Pro
- Division of Hematology, Thomas Jefferson University, Philadelphia, USA
| |
Collapse
|
15
|
Ghia P, Coutre S, Furman R, Sharman J, Cheson B, Pagel J, Hillmen P, Barrientos J, Zelenetz A, Kipps T, Flinn I, Eradat H, Lamanna N, Coiffier B, Pettitt A, Li X, Jahn T, O'Brien S, Hallek M. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed chronic lymphocytic leukemia. J Geriatr Oncol 2014. [DOI: 10.1016/j.jgo.2014.09.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Hequet O, Le QH, Rodriguez J, Dubost P, Revesz D, Clerc A, Rigal D, Salles G, Coiffier B. Development of model for analysing respective collections of intended hematopoietic stem cells and harvests of unintended mature cells in apheresis for autologous hematopoietic stem cell collection. Transfus Apher Sci 2014; 50:294-302. [PMID: 24462181 DOI: 10.1016/j.transci.2013.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2013] [Revised: 12/09/2013] [Accepted: 12/17/2013] [Indexed: 11/29/2022]
Abstract
Hematopoietic stem cells (HSCs) required to perform peripheral hematopoietic autologous stem cell transplantation (APBSCT) can be collected by processing several blood volumes (BVs) in leukapheresis sessions. However, this may cause granulocyte harvest in graft and decrease in patient's platelet blood level. Both consequences may induce disturbances in patient. One apheresis team's current purpose is to improve HSC collection by increasing HSC collection and prevent increase in granulocyte and platelet harvests. Before improving HSC collection it seemed important to know more about the way to harvest these types of cells. The purpose of our study was to develop a simple model for analysing respective collections of intended CD34+ cells among HSC (designated here as HSC) and harvests of unintended platelets or granulocytes among mature cells (designated here as mature cells) considering the number of BVs processed and factors likely to influence cell collection or harvest. For this, we processed 1, 2 and 3 BVs in 59 leukapheresis sessions and analysed corresponding collections and harvests with a referent device (COBE Spectra). First we analysed the amounts of HSC collected and mature cells harvested and second the evolution of the respective shares of HSC and mature cells collected or harvested throughout the BV processes. HSC collections and mature cell harvests increased globally (p<0.0001) and their respective shares remained stable throughout the BV processes (p non-significant). We analysed the role of intrinsic (patient's features) and extrinsic (features before starting leukapheresis sessions) factors in collections and harvests, which showed that only pre-leukapheresis blood levels (CD34+cells and platelets) influenced both cell collections and harvests (CD34+cells and platelets) (p<0.001) and shares of HSC collections and mature unintended cells harvests (p<0.001) throughout the BV processes. Altogether, our results suggested that the main factors likely to influence intended HSC collections or unintended mature cell harvests were pre-leukapheresis blood cell levels. Our model was meant to assist apheresis teams in analysing shares of HSC collected and mature cells harvested with new devices or with new types of HSC mobilization.
Collapse
Affiliation(s)
- O Hequet
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France; Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France.
| | - Q H Le
- Hospices Civils de Lyon, Department of Biostatistics, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - J Rodriguez
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - P Dubost
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - D Revesz
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France
| | - A Clerc
- Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - D Rigal
- Etablissement Français du Sang Rhône Alpes, Apheresis unit, Centre Hospitalier Lyon Sud Pierre Benite, France; Etablissement Français du Sang Rhône Alpes, Cell Therapy unit, Hôpital Edouard Herriot, Lyon, France
| | - G Salles
- Hospices Civils de Lyon, Hematological unit, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| | - B Coiffier
- Hospices Civils de Lyon, Hematological unit, Centre Hospitalier Lyon Sud, Pierre Bénite, France
| |
Collapse
|
17
|
van der Kaaij M, van Echten-Arends J, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser E, Allgeier A, Meulemans B, Lugtenburg P, Aleman B, Noordijk E, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Eghbali H, Brice P, Smit W, Sebban C, Doorduijn J, Roesink J, Gaillard I, Coiffier B, Lybeert M, Casasnovas O, André M, Raemaekers J, Henry-Amar M, Kluin-Nelemans J. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study. Hum Reprod 2013; 29:525-33. [DOI: 10.1093/humrep/det430] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Tigaud JD, Bastion Y, Coiffier B. Applications cliniques des facteurs de croissance hématopoïétiques en hémato-oncologie. Med Sci (Paris) 2013. [DOI: 10.4267/10608/4384] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
19
|
Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O, Bologna S, Christian B, Connerotte T, Récher C, Bordessoule D, Fruchart C, Delarue R, Bonnet C, Morschhauser F, Anglaret B, Soussain C, Fabiani B, Tilly H, Haioun C. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ann Oncol 2012; 24:1032-7. [PMID: 23235801 DOI: 10.1093/annonc/mds600] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was previously demonstrated. We report the results of a trial which evaluates the role of rituximab combined with ACVBP (R-ACVBP) in these patients. PATIENTS AND METHODS Untreated patients younger than 66 years with stage I or II DLBCL and no adverse prognostic factors of the age-adjusted International Prognostic Index were randomly assigned to receive three cycles of ACVBP plus sequential consolidation with or without the addition of four infusions of rituximab. RESULTS A total of 223 patients were randomly allocated to the study, 110 in the R-ACVBP group and 113 in the ACVBP group. After a median follow-up of 43 months, our 3-year estimate of event-free survival was 93% in the R-ACVBP group and 82% in the ACVBP group (P = 0.0487). Three-year estimate of progression-free survival was increased in the R-ACVBP group (95% versus 83%, P = 0.0205). Overall survival did not differ between the two groups with a 3-year estimates of 98% and 97%, respectively (P = 0.686). CONCLUSION In young patients with low-risk localized DLBCL, rituximab combined with three cycles of ACVBP plus consolidation is significantly superior to ACVBP plus consolidation alone.
Collapse
Affiliation(s)
- N Ketterer
- Department of Oncology, University Hospital, Lausanne, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, Stilgenbauer S, Thieblemont C, Vehling-Kaiser U, Doorduijn JK, Coiffier B, Forstpointner R, Tilly H, Kanz L, Feugier P, Szymczyk M, Hallek M, Kremers S, Lepeu G, Sanhes L, Zijlstra JM, Bouabdallah R, Lugtenburg PJ, Macro M, Pfreundschuh M, Procházka V, Di Raimondo F, Ribrag V, Uppenkamp M, André M, Klapper W, Hiddemann W, Unterhalt M, Dreyling MH. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520-31. [PMID: 22873532 DOI: 10.1056/nejmoa1200920] [Citation(s) in RCA: 361] [Impact Index Per Article: 30.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
BACKGROUND The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most patients have a relapse. We investigated whether a fludarabine-containing induction regimen improved the complete-remission rate and whether maintenance therapy with rituximab prolonged remission. METHODS We randomly assigned patients 60 years of age or older with mantle-cell lymphoma, stage II to IV, who were not eligible for high-dose therapy to six cycles of rituximab, fludarabine, and cyclophosphamide (R-FC) every 28 days or to eight cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) every 21 days. Patients who had a response underwent a second randomization to maintenance therapy with rituximab or interferon alfa, each given until progression. RESULTS Of the 560 patients enrolled, 532 were included in the intention-to-treat analysis for response, and 485 in the primary analysis for response. The median age was 70 years. Although complete-remission rates were similar with R-FC and R-CHOP (40% and 34%, respectively; P=0.10), progressive disease was more frequent with R-FC (14%, vs. 5% with R-CHOP). Overall survival was significantly shorter with R-FC than with R-CHOP (4-year survival rate, 47% vs. 62%; P=0.005), and more patients in the R-FC group died during the first remission (10% vs. 4%). Hematologic toxic effects occurred more frequently in the R-FC group than in the R-CHOP group, but the frequency of grade 3 or 4 infections was balanced (17% and 14%, respectively). In 274 of the 316 patients who were randomly assigned to maintenance therapy, rituximab reduced the risk of progression or death by 45% (in remission after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% confidence interval, 0.36 to 0.87; P=0.01). Among patients who had a response to R-CHOP, maintenance therapy with rituximab significantly improved overall survival (4-year survival rate, 87%, vs. 63% with interferon alfa; P=0.005). CONCLUSIONS R-CHOP induction followed by maintenance therapy with rituximab is effective for older patients with mantle-cell lymphoma. (Funded by the European Commission and others; ClinicalTrials.gov number, NCT00209209.).
Collapse
Affiliation(s)
- H C Kluin-Nelemans
- Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Tilly H, Morschhauser F, Salles G, Casasnovas RO, Feugier P, Molina TJ, Jardin F, Terriou L, Haioun C, Coiffier B. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2012; 27:252-5. [PMID: 22733106 DOI: 10.1038/leu.2012.172] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
22
|
Delarue R, Haioun C, Coiffier B, Fornecker L, Fournier M, Mounier N, Molina TJ, Bologna S, Fruchart C, Picard S, Tilly H, Bosly A. Survival effect of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: The LNH03-6B study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9048] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Coiffier B, Ribrag V, Dupuis J, Tilly H, Haioun C, Morschhauser F, Lamy T, Copie-Bergman C, Brehar O, Houot R, Lambert JM, Morarui-Zamfir R. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8017] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Horwitz SM, Coiffier B, Foss FM, Prince HM, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown LC, Padmanabhan S, Shustov AR, Nichols J, Balser J, Carroll S, Pro B. Complete responses (CR/CRu) on a phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Morschhauser F, Marlton P, Vitolo U, Lindén O, Seymour J, Crump M, Coiffier B, Foà R, Wassner E, Burger HU, Brennan B, Mendila M. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010; 21:1870-1876. [DOI: 10.1093/annonc/mdq027] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
|
26
|
Tilly H, Morschhauser F, Salles GA, Casasnovas O, Feugier P, Molina TJ, Haioun C, Coiffier B. A phase I study of escalating doses of lenalidomide combined with R-CHOP (R2-CHOP) for front-line treatment of B-cell lymphomas. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Mounier N, Heutte N, Haioun C, Feugier P, Coiffier B, Tilly H, Ferme C, Gabarre J, Morchhauser F, Gisselbrecht C. Quality of life in 269 poor-risk diffuse large B-cell lymphoma patients treated with rituximab versus observation after front-line auto transplantation: The GELA LNH98-3 randomized trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Ghesquières H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O, Reman O, Coiffier B, Tilly H, Morel P, Van den Neste E, Colin P, Haioun C, Biron P, Blay JY. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d’Etude des Lymphomes de l’Adulte (GELA). Ann Oncol 2010; 21:842-850. [DOI: 10.1093/annonc/mdp529] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
29
|
O'Connor O, Coiffier B, Zinzani P, Pinter-Brown L, Popplewell L, Shustov A, Furman R, Borghaei H, Roark S, Horwitz S. 9205 Pralatrexate treatment response by key baseline parameters in the pivotal, multi-center, phase 2 study in relapsed or refractory peripheral T-cell lymphoma (PROPEL). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71896-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
30
|
Haioun C, Mounier N, Emile JF, Ranta D, Coiffier B, Tilly H, Récher C, Fermé C, Gabarre J, Herbrecht R, Morchhauser F, Gisselbrecht C. Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma. Ann Oncol 2009; 20:1985-92. [PMID: 19567453 DOI: 10.1093/annonc/mdp237] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND This study compared the induction regimens doxorubicin, cyclophosphamide and etoposide (ACE) with doxorubicin, cyclophosphamide, vincristine, bleomycin and prednisone (ACVBP) before high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) for patients with poor-risk diffuse large B-cell lymphoma (DLBCL). A second randomisation compared rituximab with observation post-ASCT. MATERIALS AND METHODS Four hundred and seventy-six patients <60 years old with newly diagnosed CD20+ DLBCL were randomised to induction with ACE or ACVBP. Three hundred and thirty responders received HDT followed by ASCT. After ASCT, 269 patients were re-randomised to receive either maintenance rituximab or observation alone. Randomisation was stratified by the quality of response to ASCT. The primary end point of this study was event-free survival (EFS). RESULTS At a median of 4 years' follow-up from the second randomisation, there was a trend (P = 0.1) towards increased EFS for patients who received rituximab compared with observation. CONCLUSION The type of induction therapy (ACVBP or ACE) did not significantly affect overall survival at a median 51 months' follow-up.
Collapse
Affiliation(s)
- C Haioun
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Groupe Hospitalier Henri Mondor-Chenevier, Assistance Publique-Hôpitaux de Paris et Université Paris XII, Créteil, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS. A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e17575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e17575 Background: We (MC) previously established a definition of laboratory (LTLS) and clinical TLS (CTLS) and associated grading system (Cairo et al, BJH. 2004). Additionally, we recently reported an evidence based review of guidelines for the P and T of TLS (Coiffier et al, J Clin Oncol. 2008). Rasburicase (R), a recombinant urate oxidase, results in a more rapid and total reduction of uric acid (UA) compared to allopurinol (A) in children at high-risk of TLS (Goldman/Cairo et al, Blood. 2001) and a rapid reduction in UA in adults at high-risk of TLS (Coiffier et al, J Clin Oncol. 2003). It still remains to be determined which patients at risk of developing TLS should receive R versus A as initial TLS prophylaxis. Methods: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol. 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD). Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement. HRD was assigned to patients with either B-ALL, ALL/AML ≥100K/mm3, BL/LL stage III/IV, and/or high LDH, DLBCL/PTCL/MCL/ATL with bulky and elevated LDH and patients with MRD with renal impairment/involvement. MRD consisted of ALL ≤100K/mm3, AML 25–100K/mm3, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement. LRD consisted of ST (except bulky sensitive to cytotoxic therapy [MRD]), CML, MM, HL, other NHL and AML <25K/mm3. Conclusions: This medical decision tree will facilitate the practice of management of the P and T of TLS and hopefully improve the quality of care in a cost effective manner. *all authors have equal authorship and contribution [Table: see text]
Collapse
Affiliation(s)
- S. Goldman
- Medical City Children's Hospital, Dallas, TX; Hospices Civils de Lyon and Université Claude Bernard, Lyon, France; Justus-Liebig- University, Giessen, Germany; University of Texas M.D. Anderson Cancer Center, Houston, TX; Morgan Stanley Children's, Columbia University, New York, NY; on behalf of the International TLS Expert Panel
| | - B. Coiffier
- Medical City Children's Hospital, Dallas, TX; Hospices Civils de Lyon and Université Claude Bernard, Lyon, France; Justus-Liebig- University, Giessen, Germany; University of Texas M.D. Anderson Cancer Center, Houston, TX; Morgan Stanley Children's, Columbia University, New York, NY; on behalf of the International TLS Expert Panel
| | - A. Reiter
- Medical City Children's Hospital, Dallas, TX; Hospices Civils de Lyon and Université Claude Bernard, Lyon, France; Justus-Liebig- University, Giessen, Germany; University of Texas M.D. Anderson Cancer Center, Houston, TX; Morgan Stanley Children's, Columbia University, New York, NY; on behalf of the International TLS Expert Panel
| | - A. Younes
- Medical City Children's Hospital, Dallas, TX; Hospices Civils de Lyon and Université Claude Bernard, Lyon, France; Justus-Liebig- University, Giessen, Germany; University of Texas M.D. Anderson Cancer Center, Houston, TX; Morgan Stanley Children's, Columbia University, New York, NY; on behalf of the International TLS Expert Panel
| | - M. S. Cairo
- Medical City Children's Hospital, Dallas, TX; Hospices Civils de Lyon and Université Claude Bernard, Lyon, France; Justus-Liebig- University, Giessen, Germany; University of Texas M.D. Anderson Cancer Center, Houston, TX; Morgan Stanley Children's, Columbia University, New York, NY; on behalf of the International TLS Expert Panel
| | | |
Collapse
|
32
|
O'Connor O, Pro B, Pinter-Brown L, Popplewell L, Bartlett N, Lechowicz M, Savage K, Coiffier B, Saunders M, Horwitz S. PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8561] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8561 Background: Pralatrexate is a novel targeted antifolate designed to accumulate preferentially in cancer cells. PROPEL, a pivotal phase 2, non-randomized, open-label, international study, is the largest prospective study in patients (pts) with relapsed or refractory PTCL. Methods: Pts received 30 mg/m2 of pralatrexate intravenously weekly for 6 of 7 weeks, supplemented with B12 and folic acid. Primary endpoint = objective response rate (ORR); secondary endpoints = response duration, progression-free survival, and overall survival. Eligibility criteria: histologically confirmed PTCL, disease progression after ≥ 1 prior treatment, and ECOG performance status ≤ 2. Pathology was confirmed by independent central review, response to therapy was assessed by independent central review using International Workshop Criteria (IWC). Results: 115 pts were enrolled, 109 were evaluable for efficacy. 111 treated pts included 76 males (68%) and 35 females (32%). Pts had failed a median of 3 prior regimens and thus were heavily pre-treated. 78 pts (70%) failed CHOP, 18 (16%) had previous autologous stem cell transplant. 25% of pts never responded to any prior therapy; 53% did not respond to last prior therapy. The majority (59 pts, 53%) had PTCL not-otherwise specified. The ORR by central review was 27% (n = 29). 11 pts (10% overall, 38% of responders) had a complete response (CR), 18 pts (17%) had a partial response (PR), and 23 (21%) had stable disease. ORR by investigators assessment was 39% (n = 42). The median duration of response cannot be accurately estimated at this time, though responses of > 1 year have been observed. 69% of responses were after just 1 cycle. 5 responding pts went on to transplant. The most frequent Grade (Gr) 3–4 adverse events were mucosal inflammation (Gr 3 = 17%, Gr 4 = 4%) and thrombocytopenia (Gr 3 = 14%, Gr 4 = 19%). Conclusions: The results of PROPEL show that pralatrexate exhibits substantial activity in pts with relapsed or refractory PTCL, as assessed by a rigorous central review, with durable CRs /PRs, irrespective of the amount of prior therapy. [Table: see text]
Collapse
Affiliation(s)
- O. O'Connor
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B. Pro
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L. Pinter-Brown
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - L. Popplewell
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - N. Bartlett
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Lechowicz
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - K. Savage
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - B. Coiffier
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - M. Saunders
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| | - S. Horwitz
- Columbia University, New York, NY; M. D. Anderson Cancer Center, Houston, TX; University of California at Los Angeles, Los Angeles, CA; City of Hope, Duarte, CA; Washington University, St. Louis, MO; Emory University, Atlanta, GA; British Columbia Cancer Agency, Vancouver, BC, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Allos Therapeutics, Westminster, CO; Memorial Sloan-Kettering Cancer Center, New York, NY
| |
Collapse
|
33
|
Mounier N, Gisselbrecht C, Fitoussi O, Belhadj K, Feugier P, Coiffier B, Tilly H, Casasnovas O, Fermé C, Briere J, Haioun C. Benefit of rituximab combined to ACVBP (R-ACVBP) over ACVBP in 209 poor- risk BDLC NHL patients treated with up-front consolidative autotransplantation: A GELA phase II trial (LNH 2003–3). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8507] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8507 Background: Rituximab (R) combined with CHOP improves survival in DLBCL pts. More intensive regimen followed by auto transplantation have been used in patients < 60y with 2–3 adverse age-adjusted International-Prognostic-Index (aa-IPI) factors, providing a 5y OS of 65% (CI 60–68%), (Haioun LNH 98–3B, ASCO 2007). The objective of the present study was to assess whether or not combining R (375 mg/m2) to the dose intense ACVBP (doxorubicin 75 mg/m2 d1, cyclophosphamide 1,200 mg/m2 d1, vindesine 2 mg/m2 and bleomycin 10 mg d1 and d5, prednisone 60 mg/m2 d1-d5) also translates into a survival benefit. Methods: From 01/2004 to 12/2005, 209 DLCBL pts < 60y with DLBCL and aaIPI 2 or 3 received 4 cycles of R-ACVBP every 15 days. CR and PR pts received a consolidative BEAM and peripheral blood stem cell rescue (LNH2003–3 trial, # NCT00144807 ). Median age was 49 years, 22 % of patients presented with aa-IPI 3, 58% with IPI 3–5 (93% with elevated LDH and 54 % with extranodal sites >1). CR rate after induction was 61%, PR rate 24% leading to an overall response rate of 84% (176 pts). Collection failure was observed in 18 pts (10%). 155 pts received auto transplantation, representing 75% of the study population. Results: With a median follow-up of 27 months, according to the updated IWC 2007, 3y PFS and OS were estimated at 76% (CI 69–81%) and 81% (CI 75–86%), respectively. A case-controlled study was performed by matching the present R-ACVBP population with ACVBP patients selected from the LNH-98–3 trial. Patients were fully matched (1:1) on histology, aa-IPI score, gender, age and follow-up duration. 3y PFS was higher in R-ACVBP than in ACVBP patients: 75% (CI 67–81%) vs 58% (CI 50–65%), p=0.0003. 3y OS were estimated at 78% (CI 71–84%) vs 67% (CI 58–74%), p=0.05. The gain in 3y OS was significant in patients who received auto transplantation: 89% (CI 81–93%) vs 77% (CI 67–84%), p=0.02. Conclusions: These results with R-ACVBP induction and consolidative auto-transplantation suggest a major survival benefit which needs confirmatory prospective study. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. Mounier
- CHU L'Archet, Nice, France; GELA, Paris, France
| | | | - O. Fitoussi
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - K. Belhadj
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - P. Feugier
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - B. Coiffier
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - H. Tilly
- CHU L'Archet, Nice, France; GELA, Paris, France
| | | | - C. Fermé
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - J. Briere
- CHU L'Archet, Nice, France; GELA, Paris, France
| | - C. Haioun
- CHU L'Archet, Nice, France; GELA, Paris, France
| |
Collapse
|
34
|
Delmer A, Fitoussi O, Gaulard P, Laurent G, Bordessoule D, Morschhauser F, Ferme C, Tilly H, Gisselbrecht C, Coiffier B. A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05–1T trial. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8554] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8554 Background: Patients with peripheral T/NK cell lymphomas (PTCL) still have a dismal prognosis with 5-yr survival less than 30% in most cases. No alternative regimen has been proven superior to CHOP so far. This multicenter phase II study was carried out to assess efficacy and safety of bortezomib in combination with an intensified CHOP-like regimen. Methods: Pts aged 18 to 65 yrs with previously untreated PTCL were planned to receive 4 bi-monthly cycles of ACVBP (doxorubicine 75 mg/m2 D1, cyclophosphamide 1200 mg/m2 D1, vindesine 2 mg/m2 D1 and D5, bleomycine 10 mg D1 and D5 and prednisone D1 to D5) followed by a sequential consolidation consisting of HD methotrexate (2 courses), etoposide + ifosfamide (4 courses) and cytarabine (2 courses) at 2 weeks intervals. Bortezomib 1.5 mg/m2 was administered at D1 and D5 of each ACVBP cycle, and then at D1, D8 and D15 every 4 weeks during consolidation phase for a total of 20 injections during the whole treatment. Results: 57 eligible pts (M 38, F 19, median age 52.5 yrs) with mostly AITL and PTCL NOS subtypes were enrolled between January 2006 and November 2007; 78% had stage III-IV disease and 53% had aaIPI ≥ 2. Forty six pts (81%) have completed induction treatment with ACVBP and only 28 (49%) the consolidation phase, mainly for disease progression. The CR + CRu rate was 45% after induction and 46% after consolidation. As of November 14th, 2008, 22 pts (39%) have died, mostly from lymphoma. The median percentage of planned dose of bortezomib received was 98% during ACVBP induction where the vinca alkaloid used was vindesine, and ranged from 90 to 95% during the consolidation courses. The dose intensity of bortezomib was 84.3% during induction, similar to that of doxorubicine and cyclophosphamide. Thrombocytopenia was more pronounced than previously observed with ACVBP alone but no life-threatening hemorrhagic event occurred. Conclusions: The combination of bortezomib with ACVBP is feasible without neurological or platelet unexpected toxicities. The response rate of such a regimen in PTCL does not appear higher than previously observed with ACVBP alone in our historical cohort. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Delmer
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - O. Fitoussi
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - P. Gaulard
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - G. Laurent
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - D. Bordessoule
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - F. Morschhauser
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - C. Ferme
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - H. Tilly
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - C. Gisselbrecht
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| | - B. Coiffier
- Hôpital Robert Debré, Reims, France; Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; Hôpital Henri Mondor, Créteil, France; Hôpital Purpan, Toulouse, France; Hôpital Dupuytren, Limoges, France; Hôpital Claude Huriez, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Henri Becquerel, Rouen, France; Hôpital Saint-Louis, Paris, France; Hôpital Lyon Sud, Pierre-Bénite, France
| |
Collapse
|
35
|
Larouche J, Berger F, Chassagne-Clement C, Sebban C, Ghesquieres H, Salles G, Coiffier B. Lymphoma recurrence 5 years or more following diffuse large B-cell lymphoma: Clinical characteristics and outcome. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8562 Background: Diffuse large B-cell lymphoma (DLBCL) usually relapses early following treatment but some relapses happen 5 years or later. Few data exist regarding clinical characteristics and outcome of these patients (pts). Methods: We performed a retrospective analysis of all pts from two centers in Lyon/France between 1980–2003 who presented a biopsy proven relapse 5 years or later following diagnosis of DLBCL. All available biopsies were revised and immunohistochemistry (IHC) completed. Results: Among 1492 pts with DLBCL, 54 were eligible. Clinical characteristics at diagnosis were: median age 57 y; stage I-II 63% (34/54); IPI low/low intermediate 84% (41/49) and extranodal involvement (EN) 66% (35/53). IHC at diagnosis: CD20 100% (46/46), CD10 28% (10/36), bcl-6 53% (9/17), MUM1 48% (11/23), bcl-2 68% (19/28), germinal-center phenotype (GC) 57% (12/21) and non-GC 43% (9/21). 47/53 received CHOP/ACVBP-like regimens, 1 autologous transplantation (ASCT) and 1 rituximab. Median time from diagnosis to relapse was 7.4 years (5–20.5 years). 44 pts (81%) had DLBCL histology at time of relapse and 10 pts (19%) indolent histology. MUM1 expression at diagnosis was associated with DLBCL histology at relapse (p=0.037). Clinical characteristics at relapse were: median age 66 y; stage I-II 48% (26/54); 73% (31/43) with DLBCL at relapse had EN. 54% (15/28) with DLBCL at relapse had a GC phenotype and 46% (13/28) a non-GC phenotype. Treatment at relapse included rituximab in 21/54 and ASCT in 15/54 with 7 pts receiving both. Estimated 5-year event-free survival (EFS) and overall survival (OS) after relapse were 25% and 35% for all pts. Pts with DLBCL histology at relapse had an estimated 5-year EFS and OS of 18% and 28%. Pts with indolent histology had an estimated 5-year EFS and OS of 55% and 67%. Conclusions: Patients with DLBCL who present a late relapse usually had localized stage, favorable IPI and extranodal involvement at diagnosis. However, even if initial characteristics at time of first treatment were favorable, outcome of pts with DLBCL at time of relapse remains poor and aggressive treatment, such as ASCT, should be pursue whenever possible. Some patients relapsed with indolent histology and have a better outcome. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Larouche
- Centre hospitalier affilié universitaire de Québec, Quebec, QC, Canada; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Centre Léon-Bérard, Lyon, France
| | - F. Berger
- Centre hospitalier affilié universitaire de Québec, Quebec, QC, Canada; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Centre Léon-Bérard, Lyon, France
| | - C. Chassagne-Clement
- Centre hospitalier affilié universitaire de Québec, Quebec, QC, Canada; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Centre Léon-Bérard, Lyon, France
| | - C. Sebban
- Centre hospitalier affilié universitaire de Québec, Quebec, QC, Canada; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Centre Léon-Bérard, Lyon, France
| | - H. Ghesquieres
- Centre hospitalier affilié universitaire de Québec, Quebec, QC, Canada; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Centre Léon-Bérard, Lyon, France
| | - G. Salles
- Centre hospitalier affilié universitaire de Québec, Quebec, QC, Canada; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Centre Léon-Bérard, Lyon, France
| | - B. Coiffier
- Centre hospitalier affilié universitaire de Québec, Quebec, QC, Canada; Centre Hospitalier Lyon-Sud, Pierre-Bénite, France; Centre Léon-Bérard, Lyon, France
| |
Collapse
|
36
|
Bathelier E, Thomas L, Balme B, Coiffier B, Salles G, Berger F, Ffrench M, Sebban C, Biron P, Dalle S. Asymptomatic bone marrow involvement in patients presenting with cutaneous marginal zone B-cell lymphoma. Br J Dermatol 2008; 159:498-500. [DOI: 10.1111/j.1365-2133.2008.08659.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Jais JP, Haioun C, Molina TJ, Rickman DS, de Reynies A, Berger F, Gisselbrecht C, Brière J, Reyes F, Gaulard P, Feugier P, Labouyrie E, Tilly H, Bastard C, Coiffier B, Salles G, Leroy K. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008; 22:1917-24. [PMID: 18615101 DOI: 10.1038/leu.2008.188] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Gene expression profiles have been associated with clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated with anthracycline-containing chemotherapy. Using Affymetrix HU133A microarrays, we analyzed the lymphoma transcriptional profile of 30 patients treated with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and 23 patients treated with rituximab (R)-CHOP in the Groupe d'Etude des Lymphomes de l'Adulte clinical centers. We used this data set to select transcripts showing an association with progression-free survival in all patients or showing a differential effect in the two treatment groups. We performed real-time quantitative reverse transcription-PCR in the 23 R-CHOP samples of the screening set and an additional 44 R-CHOP samples set to evaluate the prognostic significance of these transcripts. In these 67 patients, the level of expression of 16 genes and the cell-of-origin classification were significantly associated with overall survival, independently of the International Prognostic Index. A multivariate model comprising four genes of the cell-of-origin signature (LMO2, MME, LPP and FOXP1) and two genes related to immune response, identified for their differential effects in R-CHOP patients (APOBEC3G and RAB33A), demonstrated a high predictive efficiency in this set of patients, suggesting that both features affect outcome in DLBCL patients receiving immunochemotherapy.
Collapse
Affiliation(s)
- J-P Jais
- Service de Biostatistique, AP-HP, hôpital Necker, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Goldenberg DM, Chang C, Rossi EA, Cardillo TM, Wegener WA, Teoh N, Leonard JP, Fayad LE, Coiffier B, Morschhauser F. Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Hess G, Romaguera JE, Verhoef G, Herbrecht R, Crump M, Strahs A, Clancy J, Hewes B, Coiffier B. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator’s choice therapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.8513] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traullé C, Espinouse D, Coiffier B. Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008; 19:774-9. [PMID: 18065404 DOI: 10.1093/annonc/mdm563] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
MESH Headings
- Adrenal Cortex Hormones/therapeutic use
- Aged, 80 and over
- Anthracyclines/administration & dosage
- Antibiotics, Antineoplastic/administration & dosage
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Chemotherapy, Adjuvant
- Comorbidity
- Diagnosis, Differential
- Disease Progression
- Female
- Humans
- Lymphoma, Large B-Cell, Diffuse/diagnosis
- Lymphoma, Large B-Cell, Diffuse/therapy
- Lymphoma, Non-Hodgkin/diagnosis
- Lymphoma, Non-Hodgkin/drug therapy
- Lymphoma, Non-Hodgkin/mortality
- Lymphoma, Non-Hodgkin/radiotherapy
- Lymphoma, Non-Hodgkin/surgery
- Lymphoma, Non-Hodgkin/therapy
- Male
- Prognosis
- Radiotherapy, Adjuvant
- Retrospective Studies
- Survival Analysis
- Treatment Outcome
Collapse
Affiliation(s)
- C Thieblemont
- Département d'Hématologie Clinique, Assistance Publique des Hôpitaux de Paris, Hôpital Saint-Louis, Institut Universitaire d'Hématologie, Paris.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008; 19:964-9. [PMID: 18296419 DOI: 10.1093/annonc/mdn031] [Citation(s) in RCA: 149] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Vorinostat has demonstrated activity in refractory cutaneous T-cell lymphoma. In a phase I trial, an encouraging activity in diffuse large-B-cell lymphoma (DLBCL) was noted. PATIENTS AND METHODS We carried out a phase II trial (NCT00097929) of oral vorinostat 300 mg b.i.d. (14 days/3 weeks or 3 days/week) in patients with measurable, relapsed DLBCL who had received two or more systemic therapies. Response rate and duration (DOR), time to progression (TTP) and safety were assessed. RESULTS Eighteen patients were enrolled (median age: 66 years; median prior therapies: 2). Seven received 300 mg b.i.d. 14 days/3 weeks, but four had grade 3 or 4 toxicity (dose-limiting toxicity, DLT). The schedule was amended to 300 mg b.i.d. 3 days/week), and none had DLT. One achieved a complete response (TtR = 85 days; DOR =or >468 days) and one had stable disease (301 days). Sixteen discontinued for progressive disease; median TTP was 44 days. Median number of cycles was 2 (1 to >19). Common drug-related adverse experiences (AEs; mostly grade 1/2) were diarrhea, fatigue, nausea, anemia and vomiting. Three patients had dose reduction; none discontinued for drug-related AEs. Drug-related AE >or=grade 3 included thrombocytopenia (16.7%) and asthenia (11.1%). CONCLUSION Vorinostat was well tolerated at 300 mg b.i.d. 3 days/week or 200 mg b.i.d. 14 days/3 weeks but had limited activity against relapsed DLBCL.
Collapse
Affiliation(s)
- M Crump
- Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2007; 22:487-95. [PMID: 18094718 DOI: 10.1038/sj.leu.2405068] [Citation(s) in RCA: 204] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.
Collapse
Affiliation(s)
- E Matutes
- Section of Haemato-Oncology, Institute of Cancer Research, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Nowak J, Kalinka-Warzocha E, Juszczyński P, Mika-Witkowska R, Zajko M, Graczyk-Pol E, Coiffier B, Salles G, Warzocha K. Haplotype-specific pattern of association of human major histocompatibility complex with non-Hodgkin's lymphoma outcome. ACTA ACUST UNITED AC 2007; 71:16-26. [PMID: 17971052 DOI: 10.1111/j.1399-0039.2007.00954.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In the previous studies, some human major histocompatibility complex (MHC) genes such as TNF, LTA and human leukocyte antigen (HLA)-DR2 genes and A1-B8-TNF(-308A) haplotype were implied in non-Hodgkin's lymphoma (NHL) outcome. In the current study, we have assigned most probable six-locus haplotypes determined by HLA-A, -Cw, -B and -DRB1 highly polymorphic genes and non-HLA LTA(+252) and TNF(-308) single nucleotide polymorphisms (SNPs) in 152 NHL Caucasian French patients. We have broadly mapped the MHC region by its component blocks and tagging alleles. Ten frequent (with haplotype frequency >1%) six-locus extended haplotypes (EHs) were revealed in NHL patients. The only two adjacent locus fragment of 8.1 EH associated with shortened freedom from progression (FFP) was B*08-LTA(+252G) (P= 0.0084, RR = 2.45). Interestingly, 305-kbp-long, four-locus fragment of 8.1 EH, Cw*07-B*08-LTA(+252G)-TNF(-308A) block was much strongly associated with shortened FFP (P= 0.00045, RR = 3.26). The analysis of further extended haploblocks comprising five or six loci showed weaker association with outcome measures, suggesting linkage disequilibrium to be the cause of DRB1*03 and A*01 allele associations. In contrast, all fragments of 7.1 EH influenced FFP favorably with top association of TNF(-308G) allele. In multivariate analysis, only Cw*07-B*08-LTA(+252G)-TNF(-308A) and TNF(-308G)-DRB1*01 haplotypes remained predictive for shortened FFP (P= 0.024 and 0.027, respectively) and independent of International Prognostic Index (P= 0.00044). This study reveals that the block composition of EHs may cause important functional differences for NHL outcomes. Further study will be required in NHL patients by fine mapping with dense microsatellite or SNP tags to define susceptibility genes in associating regions.
Collapse
Affiliation(s)
- J Nowak
- Laboratory of Immunogenetics, Institute of Haematology and Transfusion Medicine, Warsaw, Poland
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Crump M, Coiffier B, Jacobsen E, Sun L, Ricker J, Xie H, Frankel S, Randolph S, Cheson B. 6003 ORAL Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL). EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71294-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
45
|
Tilly H, Coiffier B, Michallet AS, Radford JA, Geisler CH, Gadeberg O, Dalseg A, Steenken EJ, Worsaae Dalby L. Phase I/II study of SPC2996, an RNA antagonist of Bcl-2, in patients with advanced chronic lymphocytic leukemia (CLL). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.7036] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7036 Background: SPC2996 is a novel Bcl-2 mRNA antagonist, based on the high affinity RNA analogue, Locked Nucleic Acid (LNA), being developed by Santaris Pharma for the treatment of CLL. Bcl-2 expression is typically high in CLL cells and epidemiologic data suggest that over expression of Bcl-2 is associated with a less favourable outcome in this disease. Methods: The study was an international, multicenter, dose escalating phase I/II study. Included were patients with relapsed or refractory Chronic Lymphocytic Leukemia requiring therapy, with a screening blood sample showing circulating lymphocyte counts of > 5×109/L and expressing the phenotype CD5+CD20+CD23+. Number of patients: 3 at the first two dose levels and 6 at the following levels. The patients received 6 intravenous infusions over a 2 week period with a 6 months follow up period. Assessments included: physical examinations, ECG, CT-scan, flow cytometry, PK, mRNA Bcl-2, clinical chemistry and hematology. Results: A total of 25 patients have been treated with the last patient completing treatment on 29 September 2006. Final data will be presented at ASCO. Preliminary data show a patient population with mean age 63.6 years; 68 % male; median 6.5 years of disease; median 3 prior therapies. Dose escalation was stopped after group E (4 mg/kg/dose) due to 2 DLTs in this group. A decrease in lymphocyte count was observed in 6 out of 6 pts in group E, which started within 24 hrs of the first administration of the investigational drug. Four out of 6 pts showed a maximal reduction in lymphocyte count of = 50%. Lymph node data show a decrease in total lymph node SPD of = 50% in 1 out of 5 pt in group D (2 mg/kg) and 2 out of 4 pts in group E (4 mg/kg/dose). Conclusions: Treatment of CLL patients with SPC2996 gives promising results. In group E all patients responded with an immediate decrease in lymphocyte count after receiving the initial administration of 4 mg/kg. A new investigation has been started to explore other dosing regimens, giving a smaller number of higher doses. [Table: see text]
Collapse
Affiliation(s)
- H. Tilly
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| | - B. Coiffier
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| | - A. S. Michallet
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| | - J. A. Radford
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| | - C. H. Geisler
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| | - O. Gadeberg
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| | - A. Dalseg
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| | - E. J. Steenken
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| | - L. Worsaae Dalby
- Centre Henri Becquerel, Rouen, France; Centre Hospitalier Lyon Sud, Pierre Benite, France; Christie Hospital, Manchester, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Vejle Sygehus, Vejle, Denmark; KAS Herlev, Herlev, Denmark; Santaris Pharma A/S, Hoersholm, Denmark
| |
Collapse
|
46
|
Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD. Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL): Final results of a phase II trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18511] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18511 Background: Vorinostat (Zolinza™) is a histone deacetylase inhibitor (HDACI) approved in the US for the treatment of cutaneous manifestations in patients (pts) with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following 2 systemic therapies. Clinical responses with vorinostat have been reported in other lymphoma subtypes. Methods: Open-label, single-arm, nonrandomized Phase II trial of oral vorinostat 300 mg bid (initially 14 d/3 wks; amended to 3 d/wk) until disease progression or intolerable toxicity. Eligibility: measurable, relapsed/refractory DLBCL; = 2 prior systemic therapies; adequate hematologic, hepatic and renal function. Pts who had prior HDACI treatment, allogeneic transplant, or had failed > 3 prior therapies were excluded. Primary endpoint: objective response rate (ORR) measured by CT/PET. Secondary endpoints: assessment of response duration (DOR), time to progression (TTP), time to response (TTR) and safety. Results: Eighteen pts (median age, 66 y [range, 59–86 y]; median 2 prior systemic therapies) were enrolled from 5/05 - 3/06 at 8 centers. Seven pts were initially treated with 300 mg bid 14 d/3 wks, but 4 had DLT (Gr 3 muscle spasms; Gr 4 thrombocytopenia, n = 3). The schedule was amended to 300 mg bid 3 d/wk and no other pt had DLT. One pt on the 3d/wk schedule achieved a CR (TTR = 85 d; DOR = 225+ d) and the ORR was 5.6%. One pt had SD for 301 d. Sixteen pts discontinued (DC) due to PD; median TTP for all pts was 44 d. Median number of treatment cycles was 2 (range, 1–14+). Two pts received > 6 cycles (126 d). Common drug-related adverse experiences (AE; mostly = Gr 2) were diarrhea (61%), fatigue (50%), nausea (39%), anemia (33%) and vomiting (33%). Three pts had dose reduction (300 -> 200 mg bid 14 d/3 wks) and none DC due to a drug-related AE. Drug-related AE = Gr 3 included thrombocytopenia (n = 3; 300 mg bid 14 d/3 wk) and asthenia (n = 2; 300 mg bid 3 d/wk). Two pts died on study of causes unrelated to drug: PD + GI hemorrhage (d 40) and acute myocardial infarction (d 95). Conclusion: Vorinostat has modest activity in pts with relapsed DLBCL and is well tolerated at 300 mg bid 3 d/wk or 200 mg bid 14 d/3 wks. The optimal dose/schedule and predictive response biomarkers require further study. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Crump
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| | - B. Coiffier
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| | - E. D. Jacobsen
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| | - L. Sun
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| | - J. L. Ricker
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| | - H. Xie
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| | - S. R. Frankel
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| | - S. S. Randolph
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| | - B. D. Cheson
- Princess Margaret Hospital, Toronto, ON, Canada; Centre Hospitalier Lyon Sud, Lyon, France; Dana-Farber Cancer Institute, Boston, MA; Merck Research Laboratories, Whitehouse Station, NJ; Georgetown University Hospital, Washington, DC
| |
Collapse
|
47
|
Cairo MS, Cornelis M, Baruchel A, Bosly A, Cheson B, Pui C, Ribera JM, Rule S, Younes A, Coiffier B. Risk assessment and medical decision model for prophylaxis and treatment of hyperuricemia and tumor lysis syndrome (TLS): International expert panel analysis. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.17006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17006 Background: Hyperuricemia, a major component of TLS, has historically been prevented and treated using allopurinol and alkalinization, and recently managed effectively by rasburicase (recombinant urate oxidase) in children and adults at high risk of TLS. We sought to determine the risk factors associated with TLS and develop a risk adapted medical decision model for the prevention and treatment of hyperuricemia in TLS. Methods: TLS risk scoring was performed by an expert panel, based on an odds ratio evaluation of 68 patient characteristics and cancers with known TLS risk. The RAND Appropriateness Method (RAM) (1–3 inappropriate, 4–6 uncertain, 7–9 appropriate) was utilized to investigate the appropriateness of prevention and treatment in 92 different scenarios. All appropriateness ratios were validated using a set of 36 clinical cases. The strategies analyzed included no therapy, hydration (± diuretics [DI]), rasburicase, allopurinol, and allopurinol + alkalinization. Results: Risk factors (±SD) identified included age ≥ 60 years (1.6±0.5), decreased renal function (2.7±1.1), renal tumor infiltration (1.5±0.3), initial cytoreductive therapy (2.5±1.2), acute lymphoblastic leukemia with WBC ≥50x109/L [Burkitt 8.6±5.3; pre-B 4.3±2.4; T-cell 4.6±2.8]; and non-Hodgkin lymphoma with LDH≥ 2x normal [Burkitt 6.6±3.0; lymphoblastic 3.2±2.8; diffuse large B-cell 2.4±1.9]. Hydration (± DI) was considered appropriate while no treatment and allopurinol + alkalinization were inappropriate in all scenarios. For prophylaxis, rasburicase was more appropriate than allopurinol (8.5±0.5 vs 4.9±2.1; p<0.025) in patients with hyperuricemia and/or at high risk of TLS, whereas allopurinol was more appropriate than rasburicase (6.2±1.0 vs 4.9±1.9; p<0.05) in those at low or moderate risk. In patients with TLS and normal urine output and uric acid, allopurinol and rasburicase were considered equally appropriate (5.0±0.9 vs 5.8±0.3). Conclusions: In summary, in addition to hydration (± DI), rasburicase is appropriate for patients at high risk of TLS and/or with hyperuricemia, and allopurinol for those with low risk of TLS and/or normal uric acid concentration. [Table: see text]
Collapse
Affiliation(s)
- M. S. Cairo
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - M. Cornelis
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - A. Baruchel
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - A. Bosly
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - B. Cheson
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - C. Pui
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - J. M. Ribera
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - S. Rule
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - A. Younes
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| | - B. Coiffier
- Columbia University, New York, NY; Evidis, Paris, France; Hospital Saint Louis, Paris, France; Mont-Godinne University (UCL) Belgium, Paris, France; Georgetown University Hospital, Washington, DC; St. Jude Children's Research Hospital, Memphis, TN; Hospital Germans Trias I Pujol, Barcelona, Spain; Derriford Hospital, Plymouth, United Kingdom; MD Anderson Cancer Center, Houston, TX; Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
48
|
Haioun C, Mounier N, Emile JF, Bologna S, Coiffier B, Tilly H, Recher C, Fermé C, Morschhauser F, Gisselbrecht C. Rituximab compared to observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor-risk diffuse large B-cell lymphoma: Updated results of the LNH98-B3 GELA study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8012 Background: Rituximab has been evaluated as a single agent and also in combination with chemotherapy in aggressive and indolent lymphomas with evidence of efficacy. More recently, rituximab maintenance therapy has been successfully used to keep responding patients in remission. We have shown that consolidative HDC improves outcome of poor risk responder-patients (pts) with aggressive lymphoma. Methods: The aim of the present study was to evaluate the potential benefit, as randomly compared to observation, rituximab - 375 mg/m2/week for 4 weeks - 2 months after HDC, in decreasing the relapse rate (second randomization: R2). A secondary objective was to improve the response rate before HDC using the intensified ACE chemotherapy regimen (doxorubicin 75mg/m2 d1, cyclophosphamide 1g/m2 d1-d2, etoposide 150mg/m2 d1-d3) as compared to the standard ACVBP induction regimen (R1). Four cycles were delivered every 15 days. In responding pts, HDC (mitoxantrone 45 mg/m2, cyclophosphamide 1500 mg/m2 × 4d, etoposide 250 mg/m2 × 4d and carmustine 300 mg/m2) was started between d80 and d90. Results: From 10/99 to 05/03 (closing date), 476 pts younger than 60 years with diffuse large B-cell lymphoma and aa-IPI 2 or 3 (aa-IPI 3: 29%). were enrolled. 237 pts were assigned to ACE and 239 to ACVBP. Complete response (CR+CRu) rates to induction treatment did not significantly differ between the 2 regimens (65% and 63%, respectively). Death rate during induction phase was 4% in both arms. Among the 331 pts who received HDC, 269 were randomized (R2) to receive either rituximab (n=139) or observation (n=130). 545 infusions of rituximab were administered with no clinically relevant infectious toxicity except two severe VZV infections. With a median follow-up of 4 years after R2, a trend toward a better 4y-EFS was observed in the rituximab group (80% vs 71%, p=0.098). In addition, a two-sided log-rank test stratified by aa-IPI, induction treatment and response after HDC was performed and confirmed the results of the unstratified analysis. Conclusions: We conclude that early and brief rituximab maintenance is feasible after HDC and may prolong remission status. [Table: see text]
Collapse
Affiliation(s)
- C. Haioun
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - N. Mounier
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - J. F. Emile
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - S. Bologna
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - B. Coiffier
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - H. Tilly
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - C. Recher
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - C. Fermé
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - F. Morschhauser
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| | - C. Gisselbrecht
- Hôpital Henri Mondor, Créteil, France; Hôpital Saint Louis, Paris, France; Hôpital Ambroise Paré, Paris, France; CHU Nancy Brabois, Vandoeuvre les Nancy, France; Hôpital Lyon Sud, Pierre Bénite, France; Centre Henri Becquerel, Rouen, France; Hôpital Purpan, Toulouse, France; Institut Gustave Roussy, Villejuif, France; CHU de Lille, Lille, France
| |
Collapse
|
49
|
Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon M, Coleman M, Horne H, Teoh N, Wegener WA, Goldenberg DM. Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8032] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8032 Background: An open-label, multicenter study has shown that the humanized anti-CD20 antibody, IMMU-106 (hA20), which has framework regions of epratuzumab, has a good safety and efficacy profile in NHL pts when administered once-weekly × 4 at different doses. The trial is now focused on confirming the efficacy of lower doses (80–120 mg/m2/wk × 4). Methods: A total of 68 pts (35 male, 33 female; age 34–84) received hA20 at 750 (N=3), 375 (N=27), 200 (N=11), 120 (N=21), or 80 mg/m2 (N=6). They had follicular (FL, N=47) or other (N=21) B-cell NHL, were predominantly stage III/IV (N=47) at study entry, and had received 1–8 prior treatments (median, 2), including 1 (N=40) or more (N=21) rituximab regimens (without progression within 6 months). Results: Sixty- six pts completed all 4 infusions; 1 pt progressed during treatment and withdrew, while another pt with hives and chills after prior rituximab discontinued treatment after a similar episode at 1st infusion. hA20 was generally well tolerated, with shorter infusion times (typically 2 h initially and 1 h subsequently) at lower doses. Drug-related adverse events were transient, Grade 1–2, most occurring only at 1st infusion, and there was no evidence of HAHA in 54 pts now evaluated. Mean antibody serum levels increased with dose and infusions; serum clearance at 375 mg/m2 appears similar to rituximab. Currently, 48 pts with at least 12 wks follow-up were evaluated by Cheson criteria: 32 FL pts had 15 (47%) OR's with 7 (22%) CR/CRu's, even after 2–4 prior rituximab-regimens, and 17 non-FL pts had 6 (38%) OR's, with 1 CRu in a marginal zone NHL pt. At a median follow-up of 11 mo., 9/21 pts with ORs are continuing responses, including 4 long-lived responses (15–20 mo). The evaluated pts include 17 pts at 120 mg/m2 who had 5 (29%) ORs with 3 (17%) CR/CRu's. Responses at 80 mg/m2 remain to be evaluated, but B-cell depletion occurs after the 1st infusion even at this low dose. Conclusions: hA20 appears well-tolerated, with no evidence of significant adverse events other than minor infusion reactions, even at short infusion times. B-cell depletion and responses have occurred at all doses evaluated, with no clear-cut evidence of a dose-response. As such, the study is continuing to confirm the efficacy of lower doses. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Morschhauser
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - J. P. Leonard
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - L. Fayad
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - B. Coiffier
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - M. Petillon
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - M. Coleman
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - H. Horne
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - N. Teoh
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - W. A. Wegener
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| | - D. M. Goldenberg
- Service des Maladies du Sang Centre Hospitalier Re, Lille, France; Weill Medical College of Cornell University, New York, NY; MD Anderson Cancer Center, Houston, TX; Centre Hospitalier Lyon Sud, Lyon, France; Immunomedics, Inc., Morris Plains, NJ
| |
Collapse
|
50
|
Coiffier B, Feugier P, Mounier N, Franchi-Rezgui P, Van Den Neste E, Macro M, Haioun C, Sebban C, Bordessoule D, Tilly H. Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8009] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8009 Background: The prospective randomized study LNH-98.5 was first reported in the N Engl J Med and J Clin Oncol with a median follow-up of 2 and 5 years. Here, we present the 7-year follow-up of the 399 patients included in the study. Methods: Patients had untreated diffuse large B-cell lymphoma and were 60 to 80 years old with a median age at diagnosis of 69 years. 60% had a poor risk lymphoma as defined by the aaIPI risk score of 2 or 3. 197 patients were randomized in CHOP arm and 202 in R-CHOP arm. Treatment consisted of 8 cycles of CHOP every 3 weeks with rituximab the same day in R-CHOP. Results: With a median follow-up of 7.1 years, 76% of the patients had an event in CHOP compared to 58% in R-CHOP, p=0.0002 ( Table ). 65% of patients died in CHOP arm compared to 47% in R-CHOP arm: 80% and 71% of them from lymphoma or treatment toxicity, 5% and 5% from another cancer, and 15% and 22% in CR from other causes, respectively. Survival curves show the same difference as reported before with a large difference in favour of R-CHOP ( Table ). Patients not expressing bcl-2 protein treated with R-CHOP have a statistically longer PFS but only a trend for OS because they responded better to salvage treatment. No statistically significant difference was observed for patients <70, 70–74, or ≥75 years old. Patients treated with R-CHOP have good survival even with poor risk parameters: 43% are alive for age ≥75 years, 38% for PS=2, 54% for B symptoms, 47% for stage IV, 45% for high LDH level, 54% for Hb ≤10 g/dl, and 42% for high aaIPI score. Death in CR was associated with high risk aaIPI score and presence of other diseases before lymphoma diagnosis. Conclusions: This analysis confirms the long term benefit associated with the combination of rituximab and CHOP and shows that older patients must be treated as younger patients even in presence of high risk characteristics or concomitant diseases. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- B. Coiffier
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - P. Feugier
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - N. Mounier
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - P. Franchi-Rezgui
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - E. Van Den Neste
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - M. Macro
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - C. Haioun
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - C. Sebban
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - D. Bordessoule
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| | - H. Tilly
- Centre Hospitalier Lyon Sud, Pierre Benite, France; CHU de Brabois, Nancy, France; CHU Nice, Nice, France; Hôpital Saint-Louis, Paris, France; Université Catholique de Louvain, Bruxelle, Belgium; CHU Clémenceau, Caen, France; CHU Henri Mondor, Creteil, France; Centre Leon Berard, Lyon, France; Centre Hospitalier Universitaire, Limoges, France; Centre Henri Becquerel, Rouen, France
| |
Collapse
|